Transgender and gender-diverse (TGD) individuals face an elevated risk of cancer in
comparison with the general population. This increased risk is primarily attributed to an …

There is evidence that gender-affirming hormone treatment (GAHT) for transgender
individuals modulates their risk for specific malignancies including breast and prostate …

Background Cancers are a leading cause of death worldwide, and transgender individuals
are no exception. The effects of gender‐affirming hormone therapy (GAHT) on sex hormone …

The risk of certain types of cancer differs between men and women. This is obvious for
cancers that develop in sex-specific organs such as the breast, cervix, and prostate, but …

Sex hormones are crucial for the body's development and function. Therefore, many
transgender people seek hormone therapy as part of their transition. However, sex …

Graphical abstract Abstract With the increasing number of transgender and gender diverse
(TGD) individuals who are seeking gender-affirming care, there is a clear need for the …

Transgender people comprise a diverse group of individuals whose gender identity or
expression differs from that originally assigned to them at birth. Some, but not all …

Transgender and gender-diverse (TGD) individuals are at risk for breast cancer, but are less
likely to undergo screening mammograms and appear to suffer poorer cancer-related …

Transgender health research is experiencing growing pains. More transgender people have
been able to access careers as health professionals or researchers in recent years …

Background The medical transition undergone by a transgender person may influence their
risk of breast or reproductive cancer. Objectives To assess breast and reproductive cancer …